Table 1 Antibiotics for treating patients with IAIs based upon susceptibility. Use local antibiogram data for choosing optimal antibiotics in the target population
From: WSES/GAIS/SIS-E/WSIS/AAST global clinical pathways for patients with intra-abdominal infections
Antibiotic | Anaerobic coverage | Pseudomonas coverage | Non-resistant enterococci coverage | Enterobacteriaceae coverage | ESBL coverage |
|---|---|---|---|---|---|
Amikacin | − | + | − | + | +/− |
Amoxicillin/clavulanate | + | − | + | +/−a | − |
Ceftazidime/avibactam | − | +b | − | +c | + |
Ceftolozane/tazobactam | − | +b | − | + | + |
Cefotaxime | − | − | − | + | − |
Ceftazidime | − | + | − | + | − |
Ceftriaxone | − | − | − | + | − |
Ciprofloxacin | − | + | − | +/−a | − |
Eravacycline | + | − | + | +e | + |
Ertapenem | + | − | +/− | + | + |
Imipenem-cilastatin | + | + | +d | + | + |
Meropenem | + | + | +/− | + | + |
Metronidazole | + | − | − | − | − |
Piperacillin/tazobactam | + | + | + | + | +/− |
Tigecycline | + | − | + | +e | + |